TY - JOUR
T1 - Serum Calprotectin in the Evaluation of Gastrointestinal Diseases: An Ace up Your Sleeve?
AU - Saviano, Angela
AU - Migneco, Alessio
AU - Brigida, Mattia
AU - Petruzziello, Carmine
AU - Zanza, Christian
AU - Savioli, Gabriele
AU - Franceschi, Francesco
AU - Ojetti, Veronica
PY - 2024
Y1 - 2024
N2 - Background: Calprotectin (CP) is a calcium- and zinc-binding protein that plays a key role in innate immunity and in the recruitment of inflammatory cells. CP can be detected both in serum and in fecal samples. Serum CP (sCP) is more specific for autoimmune diseases, while fecal CP (fCP) has been well investigated for gastrointestinal diseases. Few studies have shown the clinical effectiveness of sCP as an acute-phase biomarker for gastrointestinal diseases. Aim: The aim of this narrative review is to discuss the role of sCP as a useful alternative biomarker of the acute-phase activity of gastrointestinal diseases and as a possible tool for screening and monitoring these diseases. Material and Methods: We searched original articles, abstracts, reviews, case reports, and clinical trials on PubMed®, Up-to-Date®, and Medscape® in the last ten years. Conclusion: We found that sCP could represent a useful biomarker in the evaluation of the inflammatory stage in patients with immune-mediated gastrointestinal diseases, but more studies are needed to promote its routine use in clinical practice as a diagnostic and prognostic biomarker as a replacement for fCP.
AB - Background: Calprotectin (CP) is a calcium- and zinc-binding protein that plays a key role in innate immunity and in the recruitment of inflammatory cells. CP can be detected both in serum and in fecal samples. Serum CP (sCP) is more specific for autoimmune diseases, while fecal CP (fCP) has been well investigated for gastrointestinal diseases. Few studies have shown the clinical effectiveness of sCP as an acute-phase biomarker for gastrointestinal diseases. Aim: The aim of this narrative review is to discuss the role of sCP as a useful alternative biomarker of the acute-phase activity of gastrointestinal diseases and as a possible tool for screening and monitoring these diseases. Material and Methods: We searched original articles, abstracts, reviews, case reports, and clinical trials on PubMed®, Up-to-Date®, and Medscape® in the last ten years. Conclusion: We found that sCP could represent a useful biomarker in the evaluation of the inflammatory stage in patients with immune-mediated gastrointestinal diseases, but more studies are needed to promote its routine use in clinical practice as a diagnostic and prognostic biomarker as a replacement for fCP.
KW - IBD
KW - autoimmune diseases
KW - fecal calprotectin
KW - microbiota
KW - serum calprotectin
KW - IBD
KW - autoimmune diseases
KW - fecal calprotectin
KW - microbiota
KW - serum calprotectin
UR - https://publicatt.unicatt.it/handle/10807/320478
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85194199941&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85194199941&origin=inward
U2 - 10.3390/medicina60050762
DO - 10.3390/medicina60050762
M3 - Article
SN - 1648-9144
VL - 60
SP - 1
EP - 9
JO - Medicina
JF - Medicina
IS - 5
ER -